Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil

Cestari TF, Souza CDS, Azulay-Abulafia L, Romiti R, Carvalho AVE, Silva de Castro CC, Marques SA, Antonio JR, Fabrício L, Soliman AM, Wu T, Sinvhal R, Stakias V, Song AP, Kalabic J, Martin N, Oyafuso LKM. Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. An Bras Dermatol. 2025;100(2):260-271. doi:10.1016/j.abd.2024.08.002. | PMID: N/A

This phase 3 randomized study compared the efficacy and safety of risankizumab versus methotrexate in adult patients with moderate-to-severe plaque psoriasis in Brazil, including assessing outcomes in an open-label extension period for up to one year.

Key Learning Points

• •
  Risankizumab showed superior efficacy in reducing psoriasis severity compared to methotrexate over 52 weeks.
• •
  The safety profile of risankizumab was consistent and well tolerated throughout both the double-blind and open-label phases.